Bilateral Xanthogranulomatous Pyelonephritis in a Patient With Spina Bifida and Neurogenic Bladder: A Case Report.

Am J Case RepOct 26, 2026 (epub)

Dagmawi Dereje Wale, Heera Tesfaye Erega, Iman Omer et al.

✦ AI-curated · Sources linked

Case in brief

A 30-year-old man with spina bifida and neurogenic bladder managed by intermittent catheterization presented with respiratory distress, profound anemia, and declining function. Imaging showed severe bilateral hydronephrosis, extensive renal parenchymal destruction and calcifications, and right staghorn calculi, consistent with advanced bilateral xanthogranulomatous pyelonephritis (XGP). He developed septic shock and respiratory failure; nephrostomy drainage produced purulent material, with cultures growing Morganella morganii and two Candida species. Renal failure required dialysis. Definitive surgery was deferred because of anatomical deformities, instability, and operative risk. He was discharged to long-term acute care and later died from tracheostomy-related complications.

What made this case unusual

The notable feature was advanced bilateral XGP in a patient with neurogenic bladder, accompanied by extensive renal destruction and systemic instability that made definitive surgical source control prohibitive.

Diagnostic / clinical pearl

In a patient with neurogenic bladder and impaired urologic follow-up, severe bilateral hydronephrosis with renal destruction and calcifications should raise concern for advanced XGP; bilateral disease may leave few feasible options for definitive source control.

Why it matters

The case illustrates how urinary obstruction, recurrent infection, and disrupted longitudinal follow-up may coexist with upper urinary tract deterioration, although their individual contributions to this patient's progression cannot be established.

Source

Published in Am J Case Rep. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Urology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.